HBV Rewires Liver Cancer Signaling by Altering PP2A Complexes

Adriana Pitea,Rigney E Turnham,Manon Eckhardt,Gwendolyn M Jang,Zhong Xu,Huat C Lim,Alex Choi,John Von Dollen,Rebecca S. Levin,James T Webber,Elizabeth McCarthy,Junjie Hu,Xiaolei Li,Li Che,Gary Chan,R. Katie Kelley,Danielle Swaney,Wei Zhang,Sourav Bandyopadhyay,Fabian J Theis,Xin Chen,Kevan Shokat,Trey Ideker,Nevan J Krogan,John D Gordan

DOI: https://doi.org/10.1101/2023.03.15.532845

2023-01-01

Abstract:SummaryInfection by hepatitis B virus (HBV) increases risk for liver cancer by inducing inflammation, cellular stress and cell death. To elucidate the molecular pathways by which HBV promotes cancer development and progression, we used affinity purification mass spectrometry to comprehensively map a network of 145 physical interactions between HBV and human host proteins in hepatocellular carcinoma (HCC). We find that viral proteins target host factors that are preferentially mutated in non-HBV-associated HCC, implicating cancer pathways whose interaction with HBV plays a role in HCC. Focusing on proteins that directly interact with the HBV oncoprotein X (HBx), we show that HBx remodels the PP2A phosphatase complex, altering its effect on tumor signaling. HBx excludes striatin-family regulatory subunits from PP2A, causing Hippo kinase activation and unmasking a requirement for mTOR complex 2 to maintain expression of the YAP oncoprotein in HCC. Thus, HBV rewires HCC to expose potentially targetable signaling dependencies.SignificancePrecision medicine has revolutionized cancer treatment but remains elusive for HCC. We used proteomics to define HBV/host interactions and integrated them with HCC mutations. The results implicate modifiers of HCC behavior via remodeling of host complexes and illuminate new biological mechanisms in advanced disease for therapeutic investigation.